ANALYSIS OF THE USE OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH CORONAVIRUS INFECTION

Abstract

Coronavirus infection is considered a multifactorial disease; nevertheless, thrombotic complications play an important role in the further prognosis in this category of patients. More than 20 studies have been conducted around the world that have evaluated the optimal thromboprophylaxis regimens in hospitalized patients with COVID-19. Before prescribing antithrombotic therapy, it is necessary to conduct a comprehensive assessment of the parameters of the blood coagulation system. Of course, in all cases of chronic diseases, especially in the elderly, careful monitoring of clinical symptoms and the hemostasis system is required. The data of our study indicate the possibility of using rivoraxaban and acetylsalicylic acid in prophylactic doses in the absence of the need to adjust doses and drug regimens in patients with moderate to severe COVID-19.